{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:39:22Z","timestamp":1793813962427,"version":"4.6.1"},"reference-count":34,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used in type 2 diabetes (T2D) due to their cardiorenal benefits and weight-lowering effects. However, concerns have emerged regarding their potential adverse impact on lean mass and muscle strength particularly in patients at risk for sarcopenia. This study aimed to evaluate the effects of empagliflozin on skeletal muscle mass. Secondary objectives were to assess changes in glycemic control, body weight, fat mass and handgrip strength. Materials and Methods: In this 24-week real-world observational study, 31 adult patients with T2D were assigned to either empagliflozin or non-SGLT2i treatment groups. Patients did not receive a high-protein diet, a resistance exercise program or any other weight-reducing medications such as glucagon-like peptide-1 (GLP-1)-based therapies. Anthropometric measurements, body composition via bioelectrical impedance analysis (BIA), and handgrip strength testing were performed at baseline and after 6 months. Sarcopenia was defined according to EWGSOP2 criteria. Results: The empagliflozin group showed significant improvements in HbA1c, fasting plasma glucose, body weight, waist circumference, and fat mass (p &lt; 0.05 for all). No significant changes were observed in the empagliflozin group after 6 months in appendicular skeletal muscle mass index (from 7.81 \u00b1 1.33 kg\/m2 to 7.84 \u00b1 1.38 kg\/m2, p = 0.154). No statistically significant changes were observed in handgrip strength in either group. Conclusions: Empagliflozin treatment over six months led to favorable changes in metabolic parameters and fat mass without detrimental effects on skeletal muscle mass or muscle strength. In clinical practice, the selection of antidiabetic therapies should consider individual glycemic targets, cardiovascular and renal risks, weight management, comorbidities and sarcopenia risk. Resistance exercises and adequate dietary protein intake should be recommended to preserve muscle mass in at-risk patients. Larger randomized trials are needed to confirm the long-term effects of SGLT2 inhibitors on body composition particularly in older adults.<\/jats:p>","DOI":"10.3390\/medicina61071152","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:53:13Z","timestamp":1750917193000},"page":"1152","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9144-4018","authenticated-orcid":false,"given":"Deniz","family":"\u00c7etin","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Bilgili","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"Koma\u00e7","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Yeti\u015fken","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"G\u00fcney","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"ref_1","unstructured":"International Diabetes Federation (2025). IDF Diabetes Atlas, The International Diabetes Federation. [11th ed.]. Available online: https:\/\/diabetesatlas.org."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10654-013-9771-5","article-title":"Twelve-Year Trends in the Prevalence and Risk Factors of Diabetes and Prediabetes in Turkish Adults","volume":"28","author":"Satman","year":"2013","journal-title":"Eur. J. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diabres.2018.09.010","article-title":"Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD study)","volume":"146","author":"Sonmez","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/jcsm.12838","article-title":"Anti-diabetic drugs and sarcopenia: Emerging links, mechanistic insights, and clinical implications","volume":"12","author":"Zhang","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40520-014-0281-4","article-title":"Sarcopenia: A Predictor of Mortality and the Need for Early Diagnosis and Intervention","volume":"27","author":"Filippin","year":"2015","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"155533","DOI":"10.1016\/j.metabol.2023.155533","article-title":"Epidemiology of Sarcopenia: Prevalence, Risk Factors, and Consequences","volume":"144","author":"Yuan","year":"2023","journal-title":"Metabolism"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000356760","article-title":"Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options\u2014A Mini-Review","volume":"60","author":"Ali","year":"2014","journal-title":"Gerontology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Salom Vendrell, C., Garc\u00eda Tercero, E., Moro Hern\u00e1ndez, J.B., and Cedeno-Veloz, B.A. (2023). Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment. Nutrients, 15.","DOI":"10.3390\/nu15194149"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1161\/CIRCULATIONAHA.123.064071","article-title":"Sarcopenia and Cardiovascular Diseases","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Izzo, A., Massimino, E., Riccardi, G., and Della Pepa, G. (2021). A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients, 13.","DOI":"10.3390\/nu13010183"},{"key":"ref_11","unstructured":"American Diabetes Association Professional Practice Committee (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care, 47, 158\u2013178."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Huang, L., Liu, Y., Lin, T., Hou, L., Song, Q., Ge, N., and Yue, J. (2022). Reliability and Validity of Two Hand Dynamometers When Used by Community-Dwelling Adults Aged over 50 Years. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03270-6"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European Consensus on Definition and Diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic Response to Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetic Patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40520-016-0622-6","article-title":"Measurement of Lean Body Mass Using Bioelectrical Impedance Analysis: A Consideration of the Pros and Cons","volume":"29","author":"Sergi","year":"2017","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3904\/kjim.2016.015","article-title":"Differences Among Skeletal Muscle Mass Indices Derived from Height-, Weight-, and Body Mass Index-Adjusted Models in Assessing Sarcopenia","volume":"31","author":"Kim","year":"2016","journal-title":"Korean J. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/jdi.12966","article-title":"Sarcopenia, Frailty Circle and Treatment with Sodium-Glucose Cotransporter 2 Inhibitors","volume":"10","author":"Sasaki","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/dom.13421","article-title":"Comparative Study of the Effects of Ipragliflozin and Sitagliptin on Multiple Metabolic Variables in Japanese Patients with Type 2 Diabetes: A Multicentre, Randomized, Prospective, Open-Label, Active-Controlled Study","volume":"20","author":"Tsurutani","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin Reduces Fat Mass Without Affecting Muscle Mass in Type 2 Diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zeng, Y.H., Liu, S.C., Lee, C.C., Sun, F.J., and Liu, J.J. (2022). Effect of Empagliflozin Versus Linagliptin on Body Composition in Asian Patients with Type 2 Diabetes Treated with Premixed Insulin. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-21486-9"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhang, S., Qi, Z., Wang, Y., Song, D., and Zhu, D. (2023). Effect of Sodium-Glucose Transporter 2 Inhibitors on Sarcopenia in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1203666"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12933-024-02539-x","article-title":"SGLT2 inhibition and adipose tissue metabolism: Current outlook and perspectives","volume":"23","author":"Morciano","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_23","first-page":"121","article-title":"Emerging Roles of SGLT2 Inhibitors in Obesity and Insulin Resistance: Focus on Fat Browning and Macrophage Polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.14740\/jocmr4510","article-title":"Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus","volume":"13","author":"Shaheer","year":"2021","journal-title":"J. Clin. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107703","DOI":"10.1016\/j.jdiacomp.2020.107703","article-title":"Empagliflozin Decreases the Plasma Concentration of Plasminogen Activator Inhibitor-1 (PAI-1) in Patients with Type 2 Diabetes: Association with Improvement of Fibrinolysis","volume":"34","author":"Sakurai","year":"2020","journal-title":"J. Diabetes Complicat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/gerona\/glx245","article-title":"Associations of Sarcopenia Definitions, and Their Components, With the Incidence of Recurrent Falling and Fractures: The Longitudinal Aging Study Amsterdam","volume":"73","author":"Schaap","year":"2018","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1753-0407.12402","article-title":"Increased Grip Strength with Sodium-Glucose Cotransporter 2","volume":"8","author":"Sano","year":"2016","journal-title":"J. Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pantanetti, P., Cangelosi, G., Alberti, S., Di Marco, S., Michetti, G., Cerasoli, G., Di Giacinti, M., Coacci, S., Francucci, N., and Petrelli, F. (2024). Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1394506"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/jcsm.13225","article-title":"Exercise for sarcopenia in older people: A systematic review and network meta-analysis","volume":"14","author":"Shen","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"107975","DOI":"10.1016\/j.maturitas.2024.107975","article-title":"Nutrition of aging people with diabetes mellitus: Focus on sarcopenia","volume":"185","author":"Shalit","year":"2024","journal-title":"Maturitas"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:59:01Z","timestamp":1760032741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["medicina61071152"],"URL":"https:\/\/doi.org\/10.3390\/medicina61071152","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}